(VIANEWS) – Potrero Capital Research LLC (CCB), Eagle Pharmaceuticals (EGRX), RCM Technologies (RCMT) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Potrero Capital Research LLC (CCB)

163.5% sales growth and 15.35% return on equity

Potrero Capital Research LLC’s sales growth this year is expected to be 131.8% and 42.5% for next year.

Year-on-year quarterly revenue growth grew by 92.1%, now sitting on 116.01M for the twelve trailing months.

Volume

Today’s last reported volume for Potrero Capital Research LLC is 73108 which is 93.96% above its average volume of 37692.

Potrero Capital Research LLC’s sales growth is a negative 0% for the current quarter and 163.5% for the next. The company’s growth estimates for the current quarter and the next is a negative 1.8% and 14.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.35%.

Volatility

Potrero Capital Research LLC’s last day, last week, and last month’s current intraday variation average was 0.92%, 0.93%, and 1.77%, respectively.

Potrero Capital Research LLC’s highest amplitude of average volatility was 1.62% (day), 1.71% (last week), and 3.08% (last month), respectively.

Potrero Capital Research LLC’s Stock Yearly Top and Bottom Value

Potrero Capital Research LLC’s stock is valued at $38.05 at 06:22 EST, way below its 52-week high of $54.41 and way higher than its 52-week low of $26.80.

Potrero Capital Research LLC’s Moving Average

Potrero Capital Research LLC’s value is below its 50-day moving average of $40.88 and under its 200-day moving average of $42.11.

2. Eagle Pharmaceuticals (EGRX)

87% sales growth and 17.62% return on equity

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical firm that focuses on the development and commercialization of injectable products in the areas of metabolic critical care, oncology, and other medical fields in the United States.

Eagle Pharmaceuticals’s sales growth this year is expected to be 133.8% and a negative 28.2% for next year.

Year-on-year quarterly revenue growth grew by 180.9%, now sitting on 246.17M for the twelve trailing months.

Volume

Today’s last reported volume for Eagle Pharmaceuticals is 161589 which is 16.79% above its average volume of 138355.

Eagle Pharmaceuticals’s sales growth is a negative 0% for the ongoing quarter and 87% for the next. The company’s growth estimates for the ongoing quarter and the next is 261.3% and 237.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.62%.

Volatility

Eagle Pharmaceuticals’s last day, last week, and last month’s current intraday variation average was 0.89%, 1.22%, and 2.20%, respectively.

Eagle Pharmaceuticals’s highest amplitude of average volatility was 4.53% (day), 4.21% (last week), and 4.48% (last month), respectively.

Eagle Pharmaceuticals’s Stock Yearly Top and Bottom Value

Eagle Pharmaceuticals’s stock is valued at $47.40 at 06:22 EST, way below its 52-week high of $58.25 and way higher than its 52-week low of $37.07.

Eagle Pharmaceuticals’s Moving Average

Eagle Pharmaceuticals’s worth is above its 50-day moving average of $47.11 and below its 200-day moving average of $49.47.

3. RCM Technologies (RCMT)

54.2% sales growth and 62.12% return on equity

RCM Technologies, Inc. offers business and technology solutions throughout the United States, Canada, Puerto Rico, Serbia, and other countries.

RCM Technologies’s sales growth this year is anticipated to be 56.6% and 7.6% for next year.

Year-on-year quarterly revenue growth grew by 84%, now sitting on 241.29M for the twelve trailing months.

Volume

Today’s last reported volume for RCM Technologies is 188364 which is 21.33% below its average volume of 239447.

RCM Technologies’s sales growth is a negative 0% for the current quarter and 54.2% for the next. The company’s growth estimates for the current quarter and the next is 400% and 25%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 62.12%.

Volatility

RCM Technologies’s last day, last week, and last month’s current intraday variation average was 4.69%, 6.30%, and 7.26%, respectively.

RCM Technologies’s highest amplitude of average volatility was 8.45% (day), 10.97% (last week), and 11.17% (last month), respectively.

RCM Technologies’s Stock Yearly Top and Bottom Value

RCM Technologies’s stock is valued at $24.72 at 06:22 EST, way under its 52-week high of $28.82 and way above its 52-week low of $3.56.

RCM Technologies’s Moving Average

RCM Technologies’s worth is way higher than its 50-day moving average of $17.96 and way higher than its 200-day moving average of $9.60.

4. Meta Financial Group (CASH)

33.4% sales growth and 21.02% return on equity

Meta Financial Group, Inc. is the holding company of MetaBank, which offers a variety of banking products and services throughout the United States.

Meta Financial Group’s sales growth this year is expected to be 23.3% and 12.8% for next year.

Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 554.43M for the twelve trailing months.

Volume

Today’s last reported volume for Meta Financial Group is 188105 which is 30.24% below its average volume of 269658.

Meta Financial Group’s sales growth is a negative 0% for the present quarter and 33.4% for the next. The company’s growth estimates for the present quarter and the next is a negative 31.4% and 118%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.02%.

Volatility

Meta Financial Group’s last day, last week, and last month’s current intraday variation average was 2.05%, 1.29%, and 2.17%, respectively.

Meta Financial Group’s highest amplitude of average volatility was 2.56% (day), 2.65% (last week), and 3.78% (last month), respectively.

Meta Financial Group’s Stock Yearly Top and Bottom Value

Meta Financial Group’s stock is valued at $41.90 at 06:22 EST, way under its 52-week high of $65.96 and way above its 52-week low of $36.02.

Meta Financial Group’s Moving Average

Meta Financial Group’s value is below its 50-day moving average of $45.27 and way below its 200-day moving average of $53.94.

5. Eli Lilly and Company (LLY)

11.8% sales growth and 74.02% return on equity

Eli Lilly and Company develops, manufactures and markets pharmaceutical products around the world.

Eli Lilly and Company’s sales growth this year is anticipated to be 8% and 5.4% for next year.

Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 29.32B for the twelve trailing months.

Volume

Today’s last reported volume for Eli Lilly and Company is 1699110 which is 43.13% below its average volume of 2987790.

Eli Lilly and Company’s sales growth is a negative 0% for the ongoing quarter and 11.8% for the next. The company’s growth estimates for the current quarter and the next is 8.1% and 7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 74.02%.

Volatility

Eli Lilly and Company’s last day, last week, and last month’s current intraday variation average was 1.71%, 1.34%, and 1.65%, respectively.

Eli Lilly and Company’s highest amplitude of average volatility was 2.50% (day), 1.99% (last week), and 2.68% (last month), respectively.

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $286.80 at 06:22 EST, way under its 52-week high of $324.08 and way higher than its 52-week low of $217.00.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is below its 50-day moving average of $298.17 and above its 200-day moving average of $264.19.

6. EVO Payments (EVOP)

8.6% sales growth and 7.34% return on equity

EVO Payments, Inc. is an integrated merchant acquirer/payment processor in Europe and the Americas.

EVO Payments’s sales growth this year is expected to be 12.6% and 12.3% for next year.

Year-on-year quarterly revenue growth grew by 19.5%, now sitting on 517.39M for the twelve trailing months.

Volume

Today’s last reported volume for EVO Payments is 375177 which is 88.08% above its average volume of 199477.

EVO Payments’s sales growth for the next quarter is 8.6%. The company’s growth estimates for the current quarter and the next is 28.6% and 18.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.34%.

Volatility

EVO Payments’s last day, last week, and last month’s current intraday variation average was 2.72%, 1.72%, and 2.04%, respectively.

EVO Payments’s highest amplitude of average volatility was 3.12% (day), 2.66% (last week), and 3.43% (last month), respectively.

EVO Payments’s Stock Yearly Top and Bottom Value

EVO Payments’s stock is valued at $21.70 at 06:22 EST, way below its 52-week high of $30.05 and above its 52-week low of $20.07.

EVO Payments’s Moving Average

EVO Payments’s worth is under its 50-day moving average of $22.81 and under its 200-day moving average of $23.36.

LEAVE A REPLY

Please enter your comment!
Please enter your name here